Annual Congress Barcelona 2010

Saturday, 18.09.2010
Sunday, 19.09.2010
Monday, 20.09.2010
Tuesday, 21.09.2010
Wednesday, 22.09.2010

Citations should be made in the following way: Authors. Title. Eur Respir J 2010; 36: Suppl. 54, abstract number.

Material from 2010:

4910 Abstracts
646 Slide presentations
250 Webcasts
97 Handouts
2124 e-posters
250 Multimedia files

Material from 2010: Show

Regulation of airway hyperresponsiveness and bronchodilators

Thematic Poster Session
Chairs: D. Tashkin (Los Angeles, United States of America), R. RodríGuez-Roisin (Barcelona, Spain)

Download all media

*Endotoxin from E. coli* (LPS) increases human isolated airway tone by unbalancing e- i-NANC system** L. Calzetta, M. Cazzola, L. Senis, C. D‘Ambrosio, M. G. Matera (Rome, Italy)
Expression and function of PGE₂ pathway enzymes and receptors in the guinea-pig trachea J. Säfholm, K. Stark, L. O. Cardell, S. E. Dahlén, M. Adner (Stockholm, Sweden)
Airway hyperreactivity and competition of NO synthases and arginase A. Strapkova, M. Antosova (Martin, Slovakia)
The different effect of NO-synthase inhibitors in allergen and toluene-induced airway hyperreactivity M. Antosova, A. Strapkova (Martin, Slovakia)
Allergic early phase reactions are caused by mast cells and modulate airway hyperresponsiveness B. Fuchs, J. Riley, N. Rao, L. Karlsson, G. Nilsson, S. E. Dahlén, M. Adner (Stockholm, Sweden; La Jolla, United States Of America)
Influence of endogenous corticosteroids on bronchial protective properties of β₂-agonist in patients with bronchial asthma with cold bronchial hyperresponsiveness J. M. Perelman, A. B. Pirogov, Y. O. Semirech, E. V. Ushakova (Blagoveshchensk, Russian Federation)
*5,6,7-Trihydroxy-4´-methoxy-flavanone from Baccharis retusa* (asteraceae) attenuates allergen-induced airway inflammation and hyperresponsiveness in mice** A. Toledo, A. Perini, S. Grecco, N. Pinheiro, R. Magalhães, I. Tibério, M. Martins, J. Lago, C. Prado (Brazil)
Influence of the long-acting beta 2-agonist indacaterol on the citric acid-induced cough model in conscious guinea pigs T. Bouyssou, R. Bridgewater, P. Casarosa, M. Pieper, A. Schnapp, F. Gantner (Biberach an der Riß, Germany)
Indacaterol once-daily provides superior efficacy to salmeterol: A 12-week trial S. Korn, E. Kerwin, S. Atis, C. Amos, R. Owen, C. Lassen (Germany; OR, United States Of America; , Turkey; West Sussex, United Kingdom)
Dose-related efficacy of vilanterol trifenatate (VI) in COPD N. A. Hanania, G. Feldman, W. Zachgo, J. J. Shim, C. Crim, L. Sanford, S. Lettis, F. Barnhart, B. Haumann (Houston, Spartanburg, RTP, United States Of America; Geesthacht, Germany; Seoul, Republic Of Korea; London, United Kingdom)
Evaluation of glycine allele frequency in patients with mild asthma P. Adimi Naghan, F. Fahimi, S. A. R. Nadji, N. Naderi, S. Morovvati, F. Soleimani, M. R. Masjedi (Tehran, Islamic Republic Of Iran)
A clinical study of lung cancer cases with underlying COPD in relation to the COPD phenotype M. Bando, M. Nakayama, T. Hosono, N. Mato, T. Nakaya, H. Yamasawa, Y. Sugiyama (Shimotsuke, Japan)
LAS100977, a novel β₂-agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs M. Miralpeix, M. Gómez-Angelats, M. Aparici, M. Viñals, J. Beleta, A. Gavaldà, C. Puig, H. Ryder, J. Llenas, J. Gras (Barcelona, Spain)
*Demonstration of dual pharmacology in vivo* of PF-3429281: A novel inhaled dual antimuscarinic/β₂ agonist** J. Philip, A. Gray, N. Clarke, M. Yeadon, C. Perros-Huguet (Sandwich, United Kingdom)
*The in-vitro* pharmacology of PF-3429281 – A novel inhaled dual antimuscarinic/β₂ adrenoceptor agonist** S. Patel, S. Marshall, S. Summerhill, M. Strawbridge, M. Stanley, E. Stuart, N. Clarke, M. Trevethick, M. Yeadon, C. Perros-Huguet (Sandwich, United Kingdom)
A potential role for dissociation rate from the M₃ muscarinic receptor in the onset of action of NVA237 and tiotropium D. A. Sykes, M. R. Dowling, J. Leighton-Davies, S. J. Charlton (Horsham, United Kingdom)
Muscarinic receptor selectivity of aclidinium bromide and glycopyrrolate in vitro I. Ramos, J. Beleta, D. Vilella, M. Gómez-Angelats, M. Aparici, E. Calama, C. Carcasona, M. Miralpeix, A. Gavaldà (Barcelona, Spain)
Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I E. Kerwin, A. D‘Urzo, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Medford, Lakewood, Jersey City, United States Of America; Toronto, Canada; Barcelona, Spain)
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD R. Fuhr, H. Magnussen, A. Ribera Llovera, A. Kirsten, M. Falques, C. Caracta, E. Garcia Gil (Berlin, Germany; Barcelona, Spain; Jersey City, United States Of America)
*The in-vitro* pharmacology of PF-4522971 – A novel inhaled Muscarinic M₃ Antagonist** S. Patel, S. Marshall, S. Summerhilll, M. Strawbridge, M. Stanley, E. Stuart, M. Trevethick, M. Yeadon, N. Clarke (Sandwich, United Kingdom)